Methotrexate concentrations in cerebrospinal fluid and serum, and the risk of central nervous system relapse in children with acute lymphoblastic leukaemia

Anti-Cancer Drugs

Volumn 18, Issue 8, 2007, Pages 941-948

  Jönsson, Peter ^a   Höglund, Peter ^a   Wiebe, Thomas ^a   Schrøder, Henrik ^b   Seidel, Holger ^c   Skärby, Tor ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Acute lymphoblastic leukaemia; Central nervous system relapse; Concentration in cerebrospinal fluid; Methotrexate

Indexed keywords

FOLINIC ACID; FUROSEMIDE; MERCAPTOPURINE; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER RELAPSE; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK; SERUM; STATISTICS;

ADOLESCENT; ANTIMETABOLITES, ANTINEOPLASTIC; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; LOGISTIC MODELS; MALE; METHOTREXATE; NEOPLASM RECURRENCE, LOCAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RISK;

EID: 34547661701     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3281430bd1     Document Type: Article

References (20)

1. Hryniuk WM, Bertino JR. Treatment of leukemia with large doses of methotrexate and folinic acid: clinical - biochemical correlates. J Clin Invest 1969; 48:2140-2155.
2. 2 in children with acute lymphoblastic leukemia. Cancer 1987; 60:5-13.
3. Relling MV, Fairclough D, Ayers D, Crom WR, Rodman JH, Pui CH, et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 1994; 12:1667-1672.
4. Skarby T, Jonsson P, Hjorth L, Behrentz M, Bjork O, Forestier E, et al. High-dose methotrexate: on the relationship of methotrexate elimination time vs. renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL). Cancer Chemother Pharmacol 2003; 51:311-320.
5. 2 methotrexate. A study from the EORTC Children's Leukemia Cooperative Group [erratum appears in Eur J Cancer 1991; 27:110]. Eur J Cancer 1990; 26:492-495.
6. Thyss A, Milano G, Deville A, Manassero J, Renee N, Schneider M. Effect of dose and repeat intravenous 24 hr infusions of methotrexate on cerebrospinal fluid availability in children with hematological malignancies. Eur J Cancer Clin Oncol 1987; 23:843-847.
7. Seidel H, Andersen A, Kvaloy JT, Nygaard R, Moe PJ, Jacobsen G, et al. Variability in methotrexate serum and cerebrospinal fluid pharmacokinetics in children with acute lymphocytic leukemia: relation to assay methodology and physiological variables. Leuk Res 2000; 24:193-199.
8. Gokbuget N, Hoelzer D. High-dose methotrexate in the treatment of adult acute lymphoblastic leukemia. Ann Hematol 1996; 72:194-201.
9. Gustafsson G, Schmiegelow K, Forestier E, Clausen N, Glomstein A, Jonmundsson G, et al. Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia 2000; 14:2267-2275.
10. Skarby TV, Anderson H, Heldrup J, Kanerva JA, Seidel H, Schmiegelow K, et al. High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia. Leukemia 2006; 20:1955-1962.
11. Schmiegelow K, Bjork O, Glomstein A, Gustafsson G, Keiding N, Kristinsson J, et al. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. J Clin Oncol 2003; 21:1332-1339.
12. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998; 338:499-505.
13. Evans WE, Hutson PR, Stewart CF, Cairnes DA, Bowman WP, Rivera G, et al. Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion. Clin Pharmacol Ther 1983; 33:301-307.
14. Lippens RJJ, Winograd B. Methotrexate concentration levels in the cerebrospinal fluid during high-dose methotrexate infusions: an unreliable prediction. Pediatr Hematol Oncol 1988; 5:115-124.
15. Tetef ML, Margolin KA, Doroshow JH, Akman S, Leong LA, Morgan RJ Jr, et al. Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemother Pharmacol 2000; 46:19-26.
16. Bleyer WA, Dedrick RL. Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection. Cancer Treat Rep 1977; 61:703-708.
17. Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975; 293:161-166.
18. Siegal T, Zylber-Katz E. Strategies for increasing drug delivery to the brain: focus on brain lymphoma. Clin Pharmacokinet 2002; 41:171-186.
19. Glantz MJ, Cole BF, Recht L, Akerley W, Mills P, Saris S, et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary. J Clin Oncol 1998; 16:1561-1567.
20. Clarke M, Gaynon P, Hann I, Harrison G, Masera G, Peto R, et al. CNS-directed therapy for childhood acute lymphoblastic leukemia: childhood ALL collaborative group overview of 43 randomized trials. J Clin Oncol 2003; 21:1798-1809.